Dx Partnering

Your Partner of Choice for Next-Generation Diagnostics

BioSkryb is your trusted scientific partner of choice for turning breakthrough biological discovery into validated clinical tools for the next generation of diagnostics. We provide the accuracy and completeness required to move from "detection" to "definitive characterization".

The Foundation of Diagnostic Utility:

Validated in PGT

Our ResolveDNA® solution, which includes our patented primary template-directed amplification (PTA) chemistry, is broadly used in preimplantation genetic testing (PGT), where it has set a new milestone for accuracy and sensitivity in embryo screening.

Definitive Characterization in MRD & CTCs

Move beyond simple detection to full molecular characterization. Characterize circulating tumor cells (CTCs) and measurable residual disease (MRD) to map clonal evolution, confirm antigen specificity, and identify drivers of resistance.

Resolving Sample Scarcity (FNA/FFPE)

In clinical diagnostics, sample quantity is often the limiting factor. We are working with leading biopharma and diagnostics companies to generate high-fidelity multiomic data from fine-needle aspirates (FNA) and formalin-fixed, paraffin embedded (FFPE)* samples, which allows for definitive diagnostic results where other platforms fail.

*FFPE multiomics solutions coming in 2026. Interested in early access? Contact us.

AI-ready diagnostic datasets

Generate high-fidelity, single-cell multiomic reference datasets that support algorithm development, validation, and performance benchmarking for next-generation diagnostic applications.